Indeed, TGFβ signaling is defective in 30%–40% of colon cancer patients due to defects in TGFβ RII or Smads [7,8,9], and loss or reduction of TGFβ signaling is tightly associated with the development of metastasis in patient sample studies [10,11]. The gene discussed is TGFB1; the disease is malignant colon neoplasm.